|  | 60 Min | 120 Min | 180 Min | PGLM RM |
---|---|---|---|---|---|
ΔU Na (%) | |||||
HS | Patients | 87.4 (49.5; 125.4)§ | 112.4 (72.0; 152.8)*§ | 64.6 (41.4; 87.7)§ | P = 0.122 |
 | Controls | 48.2 (7.8; 88.6)§ | 54.6 (18.4; 90.8)§ | 44.0 (20.2; 67.9)§ |  |
LS | Patients | 388.9 (108.6; 669.2) | 475.2 (133.8; 816.6) | 513.7 (145.9; 881.5) | P = 0.363 |
 | Controls | 241.3 (92.9; 389.7) | 306.8 (109.3; 504.3) | 379.0 (168.4; 589.5) |  |
ΔFE Na (%) | |||||
HS | Patients | 96.6 (63.2; 130.1)§ | 107.4 (72.8; 142.1)*§ | 75.8 (56.2; 95.4)§ | P = 0.047 |
 | Controls | 50.6 (14.0; 87.1)§ | 54.1 (21.0; 87.3)§ | 46.2 (20.6; 71.7)§ |  |
LS | Patients | 379.9 (145.4; 614.4) | 442.9 (142.6; 743.2) | 486.0 (166.5; 805.5) | P = 0.323 |
 | Controls | 238.7 (106.8; 370.6) | 286.5 (120.0; 453.0) | 365.3 (157.5; 573.1) |  |
Δu-ENaC β-CR (%) | |||||
HS | Patients | -5.2 (-15.7; 5.2) | -4.1 (-12.7; 3.8) | -3.5 (-12.0; 5.1) | P = 0.311 |
 | Controls | -1.7 (-9.6; 6.1) | 8.3 (-7.6; 23.9) | -1.8 (-10.8; 7.2) |  |
LS | Patients | 5.2 (-5.7; 16.2) | 13.9 (5.0; 22.7) | 7.9 (-0.2; 16.0) | P = 0.525 |
 | Controls | -1.5 (-16.3; 13.2) | 8.1 (-12.3; 28.5) | 7.0 (-7.3; 21.3) |  |